Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment: 177Lu-DOTATATE

Yasemin Sanli; Dilara Denizmen; Rathan M Subramaniam

doi:10.1016/j.cpet.2022.11.002

Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment: ¹⁷⁷Lu-DOTATATE

PET Clin. 2023 Apr;18(2):201-214. doi: 10.1016/j.cpet.2022.11.002.

Authors

Yasemin Sanli¹, Dilara Denizmen², Rathan M Subramaniam³

Affiliations

¹ Department of Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Millet Caddesi, Istanbul 34390, Turkey. Electronic address: yasemin.sanli@yahoo.com.
² Department of Nuclear Medicine, Istanbul Faculty of Medicine, Istanbul University, Millet Caddesi, Istanbul 34390, Turkey.
³ Dean's Office, Otago Medical School, University of Otago, Dunedin 9016, New Zealand; Department of Radiology, Duke University, Durham, NC, USA.

PMID: 36858745
DOI: 10.1016/j.cpet.2022.11.002

Abstract

177Lu-DOTA-TATE therapy is a highly effective therapy in metastatic, well-differentiated, somatostatin receptor-positive GEP-neuroendocrine tumors (NETs) with mostly tolerable adverse effects. Guidelines generally refer to peptide receptor radionuclide therapy as a second-line therapy after SSA in gastroenteric and second- or third-line therapy in pancreatic NETs to improve survival rates and quality of life. Although we do not have sufficient data, 177Lu-DOTA-TATE therapy may also have a role in high-grade NET therapy, mostly in combination with other treatments such as chemotherapy.

Keywords: (177)Lu-DOTATATE; GEP-NETs; Neuroendocrine tumors; PRRT.

Publication types

Review

MeSH terms

Humans
Neuroendocrine Tumors*
Pancreatic Neoplasms*
Quality of Life
Stomach Neoplasms*

Substances

copper dotatate CU-64
Lutetium-177